Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors
A number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We examined the survival of patients with PTCL after relapse or progression in the absence of hematopoietic stem-cell transplantation...
Uloženo v:
| Vydáno v: | Journal of clinical oncology Ročník 31; číslo 16; s. 1970 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.06.2013
|
| Témata: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | A number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We examined the survival of patients with PTCL after relapse or progression in the absence of hematopoietic stem-cell transplantation and explored factors influencing survival. The three most common subtypes encountered in North America were evaluated: PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL; anaplastic lymphoma kinase [ALK] positive and ALK negative.
After exclusions, 153 patients were analyzed (PTCL-NOS, n = 79 [52%]; AITL, n = 38 [25%]; ALK-positive ALCL, n = 11 [7%]; ALK-negative ALCL, n = 27 [16%; including ALK status unknown, n = 1]).
Median time from initial diagnosis to relapse or progression after primary therapy was 6.7 months, and median age at relapse was 66 years (ALK-positive ALCL, 39 years). Median overall survival (OS) and median progression-free survival (PFS) after relapse or progression (second PFS) were 5.5 and 3.1 months, respectively, and were only marginally better in patients who received chemotherapy at relapse (n = 89 [58%]; 6.5 and 3.7 months, respectively). Patients with good performance status (PS) of 0 or 1 (n = 47) at relapse who received chemotherapy had a more favorable OS (P < .001; median OS, 13.7 months) and PFS (P = .006; median second PFS, 5.0 months), which remained significant in multivariate analysis (OS: hazard ratio [HR], 2.09; P = .002; second PFS: HR, 1.66; P = .030).
Most patients with relapsed or refractory PTCL have poor outcomes with short survival. Select patients with good PS have more favorable outcomes with standard chemotherapy. |
|---|---|
| AbstractList | A number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We examined the survival of patients with PTCL after relapse or progression in the absence of hematopoietic stem-cell transplantation and explored factors influencing survival. The three most common subtypes encountered in North America were evaluated: PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL; anaplastic lymphoma kinase [ALK] positive and ALK negative.
After exclusions, 153 patients were analyzed (PTCL-NOS, n = 79 [52%]; AITL, n = 38 [25%]; ALK-positive ALCL, n = 11 [7%]; ALK-negative ALCL, n = 27 [16%; including ALK status unknown, n = 1]).
Median time from initial diagnosis to relapse or progression after primary therapy was 6.7 months, and median age at relapse was 66 years (ALK-positive ALCL, 39 years). Median overall survival (OS) and median progression-free survival (PFS) after relapse or progression (second PFS) were 5.5 and 3.1 months, respectively, and were only marginally better in patients who received chemotherapy at relapse (n = 89 [58%]; 6.5 and 3.7 months, respectively). Patients with good performance status (PS) of 0 or 1 (n = 47) at relapse who received chemotherapy had a more favorable OS (P < .001; median OS, 13.7 months) and PFS (P = .006; median second PFS, 5.0 months), which remained significant in multivariate analysis (OS: hazard ratio [HR], 2.09; P = .002; second PFS: HR, 1.66; P = .030).
Most patients with relapsed or refractory PTCL have poor outcomes with short survival. Select patients with good PS have more favorable outcomes with standard chemotherapy. A number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We examined the survival of patients with PTCL after relapse or progression in the absence of hematopoietic stem-cell transplantation and explored factors influencing survival. The three most common subtypes encountered in North America were evaluated: PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL; anaplastic lymphoma kinase [ALK] positive and ALK negative.INTRODUCTIONA number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We examined the survival of patients with PTCL after relapse or progression in the absence of hematopoietic stem-cell transplantation and explored factors influencing survival. The three most common subtypes encountered in North America were evaluated: PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL; anaplastic lymphoma kinase [ALK] positive and ALK negative.After exclusions, 153 patients were analyzed (PTCL-NOS, n = 79 [52%]; AITL, n = 38 [25%]; ALK-positive ALCL, n = 11 [7%]; ALK-negative ALCL, n = 27 [16%; including ALK status unknown, n = 1]).PATIENTS AND METHODSAfter exclusions, 153 patients were analyzed (PTCL-NOS, n = 79 [52%]; AITL, n = 38 [25%]; ALK-positive ALCL, n = 11 [7%]; ALK-negative ALCL, n = 27 [16%; including ALK status unknown, n = 1]).Median time from initial diagnosis to relapse or progression after primary therapy was 6.7 months, and median age at relapse was 66 years (ALK-positive ALCL, 39 years). Median overall survival (OS) and median progression-free survival (PFS) after relapse or progression (second PFS) were 5.5 and 3.1 months, respectively, and were only marginally better in patients who received chemotherapy at relapse (n = 89 [58%]; 6.5 and 3.7 months, respectively). Patients with good performance status (PS) of 0 or 1 (n = 47) at relapse who received chemotherapy had a more favorable OS (P < .001; median OS, 13.7 months) and PFS (P = .006; median second PFS, 5.0 months), which remained significant in multivariate analysis (OS: hazard ratio [HR], 2.09; P = .002; second PFS: HR, 1.66; P = .030).RESULTSMedian time from initial diagnosis to relapse or progression after primary therapy was 6.7 months, and median age at relapse was 66 years (ALK-positive ALCL, 39 years). Median overall survival (OS) and median progression-free survival (PFS) after relapse or progression (second PFS) were 5.5 and 3.1 months, respectively, and were only marginally better in patients who received chemotherapy at relapse (n = 89 [58%]; 6.5 and 3.7 months, respectively). Patients with good performance status (PS) of 0 or 1 (n = 47) at relapse who received chemotherapy had a more favorable OS (P < .001; median OS, 13.7 months) and PFS (P = .006; median second PFS, 5.0 months), which remained significant in multivariate analysis (OS: hazard ratio [HR], 2.09; P = .002; second PFS: HR, 1.66; P = .030).Most patients with relapsed or refractory PTCL have poor outcomes with short survival. Select patients with good PS have more favorable outcomes with standard chemotherapy.CONCLUSIONMost patients with relapsed or refractory PTCL have poor outcomes with short survival. Select patients with good PS have more favorable outcomes with standard chemotherapy. |
| Author | Chhanabhai, Mukesh Hamm, Jeremey Villa, Diego Shenkier, Tamara Mak, Vivien Sehn, Laurie H Klasa, Richard Connors, Joseph M Gascoyne, Randy D Savage, Kerry J |
| Author_xml | – sequence: 1 givenname: Vivien surname: Mak fullname: Mak, Vivien organization: Princess Margaret Hospital, Hong Kong, China – sequence: 2 givenname: Jeremey surname: Hamm fullname: Hamm, Jeremey – sequence: 3 givenname: Mukesh surname: Chhanabhai fullname: Chhanabhai, Mukesh – sequence: 4 givenname: Tamara surname: Shenkier fullname: Shenkier, Tamara – sequence: 5 givenname: Richard surname: Klasa fullname: Klasa, Richard – sequence: 6 givenname: Laurie H surname: Sehn fullname: Sehn, Laurie H – sequence: 7 givenname: Diego surname: Villa fullname: Villa, Diego – sequence: 8 givenname: Randy D surname: Gascoyne fullname: Gascoyne, Randy D – sequence: 9 givenname: Joseph M surname: Connors fullname: Connors, Joseph M – sequence: 10 givenname: Kerry J surname: Savage fullname: Savage, Kerry J |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23610113$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAQhi1URD9gZ0IeWRLsxI5TNlTxqUodKHPkOOfWKImD7RT1J_CvSaFITHfSPXru7p2iUWtbQOiSkpgmhNy8LFZxQmgSMxYLnrATNKE8EZEQnI_-9WM09f6dEMrylJ-hcZJmlFCaTtDXa-92ZidrbDXuZDDQBo8_TdjiDpzptuCG2TpSUNe43jfd1jYSSx3AYW2cD9hBLTsP2DrcObtx4L2x7S32Hajg-uYgrowHOTCyrbCTDnBt2000OBrsf_Zb58_RqZa1h4tjnaG3h_v14ilarh6fF3fLSDGShigjSlWKVmmmgBIpK5ULlWshRF7mep5xqQjVXKa81ErOBQdWzisOihOgaVYmM3T96x2u_ejBh6Ix_vCebMH2vqApF2zOBGEDenVE-7KBquicaaTbF3_xJd8d2nej |
| CitedBy_id | crossref_primary_10_1038_s41409_020_01133_5 crossref_primary_10_1080_10428194_2019_1700244 crossref_primary_10_3389_fimmu_2022_997482 crossref_primary_10_1182_bloodadvances_2022009445 crossref_primary_10_1007_s00277_016_2877_6 crossref_primary_10_1158_1078_0432_CCR_24_1194 crossref_primary_10_3390_jcm11185378 crossref_primary_10_1182_blood_2018_01_791335 crossref_primary_10_3390_jpm12060964 crossref_primary_10_1080_17474086_2017_1270202 crossref_primary_10_1016_j_annonc_2025_01_023 crossref_primary_10_1016_j_ctrv_2017_09_002 crossref_primary_10_3390_cancers12030702 crossref_primary_10_3109_10428194_2016_1160082 crossref_primary_10_1080_10428194_2020_1839658 crossref_primary_10_1093_annonc_mdv010 crossref_primary_10_1517_14712598_2014_953048 crossref_primary_10_7759_cureus_84058 crossref_primary_10_3389_fimmu_2023_1128172 crossref_primary_10_1007_s10238_025_01726_8 crossref_primary_10_1093_annonc_mdv237 crossref_primary_10_1007_s11912_020_00902_1 crossref_primary_10_1016_j_xcrm_2025_102029 crossref_primary_10_1111_bjh_17951 crossref_primary_10_1080_10428194_2017_1300888 crossref_primary_10_1002_hem3_70128 crossref_primary_10_1016_j_annonc_2021_12_002 crossref_primary_10_3892_ol_2019_10703 crossref_primary_10_1182_bloodadvances_2022009575 crossref_primary_10_1182_blood_2020009004 crossref_primary_10_1007_s10238_022_00805_4 crossref_primary_10_1053_j_seminhematol_2021_02_006 crossref_primary_10_1016_S2352_3026_15_00023_X crossref_primary_10_1080_17474086_2019_1643232 crossref_primary_10_1053_j_seminhematol_2021_02_003 crossref_primary_10_5021_ad_2020_32_4_337 crossref_primary_10_1038_s41568_020_0247_0 crossref_primary_10_1016_j_jtct_2024_05_006 crossref_primary_10_1038_s41409_019_0734_7 crossref_primary_10_1016_j_ejca_2022_09_008 crossref_primary_10_3109_07853890_2014_952662 crossref_primary_10_3390_cancers12082293 crossref_primary_10_1016_j_omto_2023_07_007 crossref_primary_10_1016_j_critrevonc_2024_104498 crossref_primary_10_1038_leu_2016_311 crossref_primary_10_1182_bloodadvances_2017011916 crossref_primary_10_3390_cancers16193359 crossref_primary_10_1186_s13045_020_00928_9 crossref_primary_10_1038_s41408_024_01199_0 crossref_primary_10_1007_s00277_018_3288_7 crossref_primary_10_1159_000500666 crossref_primary_10_1093_jnci_djt378 crossref_primary_10_1007_s11899_023_00710_x crossref_primary_10_1038_s41389_020_00259_x crossref_primary_10_1007_s11899_017_0389_7 crossref_primary_10_1097_MD_0000000000018650 crossref_primary_10_3389_fonc_2021_750323 crossref_primary_10_1097_PAS_0000000000000571 crossref_primary_10_1182_bloodadvances_2024012800 crossref_primary_10_1182_blood_2018_04_840538 crossref_primary_10_1080_17474086_2020_1756257 crossref_primary_10_3390_jpm12020267 crossref_primary_10_1080_10428194_2018_1537489 crossref_primary_10_1007_s11864_020_00761_9 crossref_primary_10_1007_s40265_014_0275_8 crossref_primary_10_1182_bloodadvances_2018024075 crossref_primary_10_1186_s13045_025_01697_z crossref_primary_10_4103_ijc_IJC_961_19 crossref_primary_10_1016_j_ejca_2017_06_026 crossref_primary_10_1080_10428194_2019_1622100 crossref_primary_10_1177_20406207221143025 crossref_primary_10_1016_j_hoc_2016_12_001 crossref_primary_10_3390_cancers15010220 crossref_primary_10_1185_03007995_2015_1008131 crossref_primary_10_1080_10428194_2020_1795164 crossref_primary_10_1016_j_leukres_2019_05_014 crossref_primary_10_1182_bloodadvances_2023010441 crossref_primary_10_1016_j_omton_2024_200850 crossref_primary_10_1634_theoncologist_2017_0524 crossref_primary_10_3390_cancers15030589 crossref_primary_10_1186_s40425_016_0201_6 crossref_primary_10_1111_bjh_13566 crossref_primary_10_3389_fonc_2024_1471090 crossref_primary_10_1001_jamanetworkopen_2021_9807 crossref_primary_10_1002_hon_2705 crossref_primary_10_4274_tjh_galenos_2022_2022_0052 crossref_primary_10_1371_journal_pone_0191461 crossref_primary_10_3389_fmed_2021_732727 crossref_primary_10_1177_1078155216634178 crossref_primary_10_3389_fonc_2022_944511 crossref_primary_10_1080_10428194_2020_1827241 crossref_primary_10_1158_1078_0432_CCR_16_1996 crossref_primary_10_1016_j_jaim_2024_100968 crossref_primary_10_1080_10428194_2025_2540437 crossref_primary_10_3389_fonc_2022_863269 crossref_primary_10_1002_ccr3_9159 crossref_primary_10_1097_MD_0000000000004796 crossref_primary_10_3389_fonc_2024_1494384 crossref_primary_10_1007_s11899_018_0432_3 crossref_primary_10_1182_blood_2017_08_802470 crossref_primary_10_1111_bjh_14763 crossref_primary_10_1007_s00277_024_06109_9 crossref_primary_10_1038_bmt_2016_313 crossref_primary_10_1155_2017_7292148 crossref_primary_10_1002_ajh_24895 crossref_primary_10_1080_10428194_2023_2256908 crossref_primary_10_1016_S2152_2650_24_00383_5 crossref_primary_10_1093_jncics_pky038 crossref_primary_10_3389_fphar_2022_869488 crossref_primary_10_1093_annonc_mdw011 crossref_primary_10_1016_j_ctrv_2024_102793 crossref_primary_10_1016_S2352_3026_15_00097_6 crossref_primary_10_1016_j_clml_2019_03_022 crossref_primary_10_1080_14728214_2017_1366447 crossref_primary_10_1371_journal_pone_0112148 crossref_primary_10_1038_bcj_2014_78 crossref_primary_10_1002_hon_2846 crossref_primary_10_1016_j_critrevonc_2015_12_016 crossref_primary_10_1002_hon_2963 crossref_primary_10_1182_blood_2017_05_780049 crossref_primary_10_1111_ejh_13568 crossref_primary_10_1002_cam4_5479 crossref_primary_10_1007_s00761_019_0636_8 crossref_primary_10_1007_s11899_021_00634_4 crossref_primary_10_1007_s11899_024_00743_w crossref_primary_10_3109_10428194_2014_963078 crossref_primary_10_1007_s11912_022_01310_3 crossref_primary_10_3390_cancers16193430 crossref_primary_10_1093_jnci_djt454 crossref_primary_10_3390_cancers10090339 crossref_primary_10_1002_cncr_30416 crossref_primary_10_1007_s00277_023_05536_4 crossref_primary_10_1016_S2352_3026_25_00073_0 crossref_primary_10_1038_s41392_021_00768_0 crossref_primary_10_1200_JCO_2014_59_2782 crossref_primary_10_3390_cancers15030925 crossref_primary_10_3892_ol_2014_2517 crossref_primary_10_1016_j_phrs_2025_107628 crossref_primary_10_1182_blood_2016_12_755496 crossref_primary_10_1007_s12185_017_2286_1 crossref_primary_10_1016_j_clml_2019_03_031 crossref_primary_10_1093_annonc_mdx316 crossref_primary_10_1182_blood_2013_12_542142 crossref_primary_10_1002_ajh_25043 crossref_primary_10_1038_s41375_021_01191_8 crossref_primary_10_3390_cancers13194788 crossref_primary_10_1007_s11899_018_0431_4 crossref_primary_10_1007_s00277_018_3418_2 crossref_primary_10_1586_17474086_2016_1122514 crossref_primary_10_1111_cas_13513 crossref_primary_10_1182_blood_2016_09_692541 crossref_primary_10_3390_cancers14051186 crossref_primary_10_1080_10428194_2023_2287965 crossref_primary_10_1182_blood_2014_12_617779 crossref_primary_10_1200_JCO_18_00899 crossref_primary_10_1002_ajh_24992 crossref_primary_10_1002_ajh_27345 crossref_primary_10_1007_s00761_025_01711_6 crossref_primary_10_1097_CM9_0000000000001575 crossref_primary_10_3389_fonc_2024_1461268 crossref_primary_10_14694_EdBook_AM_2015_35_e468 crossref_primary_10_1016_j_lanwpc_2021_100126 crossref_primary_10_1186_s12935_021_02275_2 crossref_primary_10_1177_1179545X17705863 crossref_primary_10_1186_s13256_016_0963_y crossref_primary_10_3322_caac_21589 crossref_primary_10_3389_fimmu_2022_1070660 crossref_primary_10_1002_acg2_6 crossref_primary_10_1093_jjco_hyaa177 crossref_primary_10_1111_bjh_13400 crossref_primary_10_1053_j_seminhematol_2013_11_010 crossref_primary_10_12688_f1000research_22257_1 crossref_primary_10_1080_17474086_2019_1583102 crossref_primary_10_1182_blood_2014_04_573089 crossref_primary_10_3390_biomedicines12050977 crossref_primary_10_1038_s41467_022_32092_8 crossref_primary_10_1182_blood_2024025484 crossref_primary_10_1080_10428194_2016_1222381 crossref_primary_10_1586_14737140_2016_1146597 crossref_primary_10_1007_s12185_020_02879_w crossref_primary_10_1016_j_blre_2021_100889 crossref_primary_10_1016_j_clml_2018_10_001 crossref_primary_10_1111_his_13463 crossref_primary_10_1136_jitc_2023_007277 crossref_primary_10_1007_s12185_020_02987_7 crossref_primary_10_1016_j_bbmt_2015_03_009 crossref_primary_10_1080_17474086_2019_1558399 crossref_primary_10_1016_j_leukres_2016_05_020 crossref_primary_10_1111_bjh_16914 crossref_primary_10_1097_MD_0000000000002318 crossref_primary_10_1200_JCO_2017_73_8195 crossref_primary_10_1038_bmt_2015_265 crossref_primary_10_1080_10428194_2017_1295143 crossref_primary_10_1158_1078_0432_CCR_24_1913 crossref_primary_10_3109_10428194_2015_1133814 crossref_primary_10_1053_j_seminhematol_2013_11_005 crossref_primary_10_1080_10428194_2018_1515937 crossref_primary_10_1053_j_seminhematol_2013_11_006 crossref_primary_10_1016_S2352_3026_24_00102_9 crossref_primary_10_1053_j_seminhematol_2013_11_009 crossref_primary_10_1186_s13045_020_00892_4 crossref_primary_10_1002_cnr2_1581 crossref_primary_10_1016_S1470_2045_14_70161_5 crossref_primary_10_1097_HS9_0000000000000461 crossref_primary_10_1182_bloodadvances_2022008524 crossref_primary_10_1016_j_revmed_2020_05_015 crossref_primary_10_1080_10428194_2017_1312379 crossref_primary_10_1007_s00761_015_2967_4 crossref_primary_10_3390_cells14171306 crossref_primary_10_1182_bloodadvances_2023011470 crossref_primary_10_3389_fonc_2023_1101441 crossref_primary_10_2217_ijh_14_31 crossref_primary_10_1007_s00432_019_02999_9 crossref_primary_10_3389_fonc_2022_874462 crossref_primary_10_1007_s12185_018_2560_x crossref_primary_10_1002_cncr_29103 crossref_primary_10_1093_jnci_djw248 crossref_primary_10_1007_s12254_022_00864_z crossref_primary_10_1002_cam4_70476 crossref_primary_10_1007_s00280_020_04172_3 crossref_primary_10_1080_17474086_2017_1283214 crossref_primary_10_1182_bloodadvances_2023012531 crossref_primary_10_1016_j_clml_2019_03_001 crossref_primary_10_1111_bjh_17896 crossref_primary_10_1080_10428194_2025_2510524 crossref_primary_10_1186_s12885_021_08607_9 crossref_primary_10_1182_blood_2016_08_692566 crossref_primary_10_1182_blood_2018_12_889741 crossref_primary_10_3389_fonc_2019_00126 crossref_primary_10_1080_10428194_2023_2245513 crossref_primary_10_1038_s41409_018_0360_9 crossref_primary_10_1016_S2352_3026_20_30207_6 crossref_primary_10_1517_14728214_2014_896337 crossref_primary_10_2500_aap_2024_45_230062 crossref_primary_10_1002_hon_2144 crossref_primary_10_1016_j_medj_2024_07_007 crossref_primary_10_1038_s41409_018_0417_9 crossref_primary_10_1371_journal_pone_0161811 crossref_primary_10_3389_fimmu_2023_1203471 crossref_primary_10_1177_0963689721999615 crossref_primary_10_1182_bloodadvances_2022008798 crossref_primary_10_3892_ol_2024_14474 crossref_primary_10_3390_cancers14092332 crossref_primary_10_1080_03007995_2021_1920380 crossref_primary_10_1200_JCO_2014_60_6327 crossref_primary_10_4103_0366_6999_239315 crossref_primary_10_3390_hematolrep17010003 crossref_primary_10_1002_iub_2130 crossref_primary_10_1080_17474086_2020_1770590 crossref_primary_10_1007_s11864_021_00873_w crossref_primary_10_1007_s00277_017_3166_8 crossref_primary_10_1053_j_seminhematol_2021_03_001 crossref_primary_10_1111_bjh_16428 crossref_primary_10_1038_s41409_018_0223_4 crossref_primary_10_1080_10428194_2017_1393671 crossref_primary_10_1038_s41408_023_00868_w crossref_primary_10_1097_CM9_0000000000002836 crossref_primary_10_1182_blood_2021015114 crossref_primary_10_1016_j_leukres_2021_106705 crossref_primary_10_1053_j_seminhematol_2020_11_008 crossref_primary_10_1111_cas_13340 crossref_primary_10_1158_1078_0432_CCR_14_3119 crossref_primary_10_3389_fonc_2023_1202964 crossref_primary_10_3960_jslrt_25013 crossref_primary_10_1182_bloodadvances_2018030577 crossref_primary_10_1182_blood_2018_07_865527 crossref_primary_10_1007_s00277_018_3559_3 crossref_primary_10_1002_hon_2560 crossref_primary_10_1080_14712598_2019_1572746 crossref_primary_10_1097_MD_0000000000016482 crossref_primary_10_1182_bloodadvances_2023011030 crossref_primary_10_3390_cells11243971 crossref_primary_10_1016_j_hoc_2016_11_002 crossref_primary_10_1097_MD_0000000000009611 crossref_primary_10_1016_j_hoc_2016_11_001 crossref_primary_10_3389_fonc_2023_1177330 crossref_primary_10_1002_hon_2687 crossref_primary_10_1016_j_clml_2015_06_008 crossref_primary_10_1111_bjh_14477 crossref_primary_10_1097_MD_0000000000024455 crossref_primary_10_12688_f1000research_12573_1 crossref_primary_10_1111_bjh_14473 crossref_primary_10_1097_CCO_0000000000000469 crossref_primary_10_1016_j_hoc_2016_11_009 crossref_primary_10_1097_PPO_0000000000000452 crossref_primary_10_1007_s00262_021_03051_x crossref_primary_10_1016_j_bbmt_2015_01_013 crossref_primary_10_1097_CCO_0000000000000473 crossref_primary_10_1080_10428194_2024_2433616 crossref_primary_10_1016_j_clml_2017_05_001 crossref_primary_10_1016_j_mayocp_2015_04_025 crossref_primary_10_1158_1078_0432_CCR_15_0033 crossref_primary_10_1002_hon_2691 crossref_primary_10_1007_s11523_019_00630_y crossref_primary_10_1016_j_annonc_2020_12_009 crossref_primary_10_1016_j_jfma_2023_07_014 crossref_primary_10_1517_13543784_2014_908184 crossref_primary_10_1007_s11899_020_00561_w crossref_primary_10_1016_S2352_3026_15_00116_7 crossref_primary_10_1038_s41591_024_03326_7 crossref_primary_10_1038_s41375_022_01545_w crossref_primary_10_1182_blood_2023021304 crossref_primary_10_1182_bloodadvances_2024015156 crossref_primary_10_1016_j_jaad_2016_06_011 crossref_primary_10_1158_1078_0432_CCR_19_2152 crossref_primary_10_1186_s13045_024_01560_7 crossref_primary_10_1055_a_2359_6020 crossref_primary_10_1182_blood_2014_12_616961 crossref_primary_10_1186_s13045_016_0266_1 crossref_primary_10_1007_s12185_022_03394_w crossref_primary_10_1200_JCO_2012_48_3883 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2012.44.7524 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 23610113 |
| Genre | Journal Article |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC |
| ID | FETCH-LOGICAL-c403t-60ccdc1d36ce10aadc87c8f7778b8f965ac01f5a35bfca975e4b9d5ec50e136b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 363 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000319657600017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Wed Oct 01 15:00:41 EDT 2025 Thu Apr 03 06:56:55 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 16 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c403t-60ccdc1d36ce10aadc87c8f7778b8f965ac01f5a35bfca975e4b9d5ec50e136b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.44.7524?role=tab |
| PMID | 23610113 |
| PQID | 1357494704 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1357494704 pubmed_primary_23610113 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-06-01 |
| PublicationDateYYYYMMDD | 2013-06-01 |
| PublicationDate_xml | – month: 06 year: 2013 text: 2013-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2013 |
| SSID | ssj0014835 |
| Score | 2.5757282 |
| Snippet | A number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1970 |
| SubjectTerms | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Disease Progression Disease-Free Survival Female Humans Lymphoma, T-Cell, Peripheral - drug therapy Lymphoma, T-Cell, Peripheral - mortality Lymphoma, T-Cell, Peripheral - pathology Lymphoma, T-Cell, Peripheral - therapy Male Middle Aged Multivariate Analysis Odds Ratio Recurrence Survival Analysis |
| Title | Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23610113 https://www.proquest.com/docview/1357494704 |
| Volume | 31 |
| WOSCitedRecordID | wos000319657600017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSxxBEG5ilOAlRo2PxIQSxJOt3Tvd0zO5SBAlBFwXXGFvS08_RFhn1h1X2J-Qf53qnpY9BQJe5tbzoGrqXd9HyBFzhueeW1pWOlCY-R4tC2YxS_EKszH0ccxEsgnV7xejUTlIBbc2jVW-2sRoqG1jQo38jGdSiVIoJs6nTzSwRoXuaqLQWCGrGYYyYaRLjZZdBFFEgs3A3IpRpJSpTYmKcfb74ibMdfVOhThVMuy7_yvAjI7mauOtr_iJfEwhJvzsdGKTvHP1FvlwnZroW-R40MFVL05guNy-ak_gGAZLIOvFNvlzO0dDgqoIjYcEwNpCqNxCwEeOgAQTGNJQ_IfJAvWiedQQWcfBP2BYCWFTZto6aGYQB8E6EJAfEPc7Z_PHcOPUIgJdW8DM3cGkqe9p8BjQxuc3s_Yzubu6HF78oom6gRrBsmeaM2Os4TbLjeNMa2sKZQqvlCqqwpe51IZxL3UmK290qaQTVWmlM5I5nuVVb4e8r5va7REoDIZMHBMvb0vMJfNKCzyrmeYWUyNh98nhqzTG-GuET9a1a-bteCmPfbLbiXQ87TA8xgFzBk1b9uU_Tn8l672OBIMyfkBWPRoG942smZfnh3b2PeocXvuD67_HS-Q_ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Survival+of+patients+with+peripheral+T-cell+lymphoma+after+first+relapse+or+progression%3A+spectrum+of+disease+and+rare+long-term+survivors&rft.jtitle=Journal+of+clinical+oncology&rft.au=Mak%2C+Vivien&rft.au=Hamm%2C+Jeremey&rft.au=Chhanabhai%2C+Mukesh&rft.au=Shenkier%2C+Tamara&rft.date=2013-06-01&rft.eissn=1527-7755&rft.volume=31&rft.issue=16&rft.spage=1970&rft_id=info:doi/10.1200%2FJCO.2012.44.7524&rft_id=info%3Apmid%2F23610113&rft_id=info%3Apmid%2F23610113&rft.externalDocID=23610113 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |